Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib

Tofacitinib is a targeted inhibitor of janus kinase (JAK), currently approved for the treatment of rheumatoid arthritis. We present a patient on treatment withtofacitinib who had an episode of classic dermatomal herpes zoster followed months later by atypical chronic cutaneous ulcers also caused by...

Full description

Saved in:
Bibliographic Details
Published inDermatology online journal Vol. 24; no. 1
Main Authors Noell, Claire, Arbeit, Robert, Kanhoush, Rima
Format Journal Article
LanguageEnglish
Published United States 15.01.2018
Online AccessGet full text

Cover

More Information
Summary:Tofacitinib is a targeted inhibitor of janus kinase (JAK), currently approved for the treatment of rheumatoid arthritis. We present a patient on treatment withtofacitinib who had an episode of classic dermatomal herpes zoster followed months later by atypical chronic cutaneous ulcers also caused by herpes zoster.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1087-2108
1087-2108
DOI:10.5070/D3241037931